/

Catalent, Inc.

CTLT US

CTLT USCatalent, Inc.

United States Composite

55.80

USD

-0.16

(-0.29%)

-7.15EPS Dil.

-7.80P/E

10.08BMarket Cap

Catalent, Inc.

CTLT

(United States Composite)

Recent

price

55.80

P/E

ratio

-7.80

div

yld

- -

ROIC.AI

Legends:

Stock price

1.01

Beta (1.0 Market)

% total return 04/19

Stock

S&P500

YTD

30.53

- -

-48.25

- -

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

- -

13.06

14.45

15.35

15.58

15.31

14.81

16.61

18.77

17.49

20.63

23.80

27.28

23.55

22.52

- -

-0.46

-0.21

-0.42

0.14

1.77

0.89

0.88

0.64

0.95

1.47

3.48

2.84

-1.41

-7.15

- -

0.11

-0.14

0.13

0.48

0.26

0.13

1.28

1.51

0.21

-0.17

-1.51

-1.26

-1.78

-1.45

- -

0.24

0.13

0.02

- -

-11.77

-11.89

-11.75

-9.38

-8.30

-7.63

-6.53

-4.95

-3.27

0.16

2.91

1.46

-3.88

- -

-15.33

-15.39

-15.57

-6.40

-5.25

-4.75

-6.41

-10.09

-2.83

3.40

3.96

3.28

2.35

- -

117

120

125

131

144

150

168

176

181

182

- -

1,532

1,695

1,800

1,828

1,831

1,848

2,075

2,463

2,518

3,094

3,998

4,802

4,263

4,098

- -

13.20

12.94

12.66

14.43

15.18

12.42

12.14

11.68

10.88

12.77

16.16

15.18

1.10

-7.37

- -

116

130

152

143

141

147

190

229

254

289

378

422

453

- -

-54

-24

-50

212

112

110

137

221

585

499

-256

-1,302

- -

2.69

- -

73.44

- -

23.26

19.03

45.00

14.38

15.00

18.18

13.82

- -

-3.53

-1.44

-2.76

0.89

11.59

6.03

5.29

3.39

5.44

7.14

14.63

10.39

-6.01

-31.77

- -

265

269

235

339

399

591

663

725

1,400

1,722

1,819

1,162

1,534

- -

2,640

2,657

2,685

1,857

1,833

2,055

2,649

2,883

2,945

3,166

4,171

4,313

4,959

- -

-351

-410

-372

634

636

724

1,087

2,288

3,506

4,274

4,775

4,611

3,687

- -

18.04

- -

2.97

- -

6.90

7.61

4.76

5.17

5.69

7.50

7.59

- -

23.45

- -

4.60

- -

23.33

18.74

9.74

9.66

11.03

20.00

14.44

- -

182.45

-65.31

- -

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'24

Dec'24

ST Debt

547

635

LT Borrowings

4,313

4,322

4,959

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

180

181

Market Capitalization

7,817

8,241

8,117

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'24

Dec'24

Total Current Assets

2,692

2,614

2,570

Cash, Cash Equivalents & STI

280

209

229

Accounts Receivable, Net

1,002

830

843

Inventories

801

822

802

Total Current Liabilities

1,530

1,534

1,036

Payables & Accruals

656

597

631

ST Debt

547

635

Deferred Revenue

167

179

214

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

9.68%

12.64%

-11.22%

Net Income, GAAP

114.35%

24.62%

-151.30%

Free Cash Flow

-7.36%

-235.53%

-45.70%

Total Cash Common Dividend

- -

Total Equity

-0.30%

38.78%

-3.43%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2022

1,025

1,217

1,273

1,313

4,802

2023

1,022

1,149

1,037

1,055

4,263

2024

982

1,024

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2022

0.54

0.55

0.78

1.07

2.84

2023

- -

0.45

-1.25

-0.60

-1.41

2024

-4.19

-1.13

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2022

0.02

- -

0.02

2023

- -

2024

- -

Business: Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Company News

Bloomberg
23 days ago
Ozempic, Novo’s $1,000 Diabetes Drug, Can Be Made for Less Than $5 a Month, Study Says
Zacks
a month ago
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Reuters
a month ago
Novo Nordisk-owner to expand in India this year
Yahoo
a month ago
The Top 3 Pharma Stocks to Buy in March 2024
Reuters
a month ago
Novo Nordisk hopes to launch experimental obesity drug this decade
Yahoo
a month ago
HIGHLIGHTS-Novo Nordisk hopes to launch experimental obesity drug this decade
Reuters
a month ago
Novo Nordisk will raise capex if Catalent deal is not completed, CFO says
Yahoo
a month ago
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
Zacks
a month ago
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Reuters
a month ago
Novo Nordisk présente de nouveaux traitements de l'obésité et fait le point sur le Wegovy
Reuters
a month ago
Novo Nordisk to present early drug trial data, Wegovy supply update
Bloomberg
a month ago
Wegovy Maker Wants Japan to Know It Has an Obesity Problem Too
Bloomberg
a month ago
Weight Loss Drugs Threatened by US Effort to Contain China

Company News

Bloomberg
23 days ago
Ozempic, Novo’s $1,000 Diabetes Drug, Can Be Made for Less Than $5 a Month, Study Says
Zacks
a month ago
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Reuters
a month ago
Novo Nordisk-owner to expand in India this year
Yahoo
a month ago
The Top 3 Pharma Stocks to Buy in March 2024
Reuters
a month ago
Novo Nordisk hopes to launch experimental obesity drug this decade
Yahoo
a month ago
HIGHLIGHTS-Novo Nordisk hopes to launch experimental obesity drug this decade
Reuters
a month ago
Novo Nordisk will raise capex if Catalent deal is not completed, CFO says
Yahoo
a month ago
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
Zacks
a month ago
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Reuters
a month ago
Novo Nordisk présente de nouveaux traitements de l'obésité et fait le point sur le Wegovy
Reuters
a month ago
Novo Nordisk to present early drug trial data, Wegovy supply update
Bloomberg
a month ago
Wegovy Maker Wants Japan to Know It Has an Obesity Problem Too
Bloomberg
a month ago
Weight Loss Drugs Threatened by US Effort to Contain China

- -

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

- -

13.06

14.45

15.35

15.58

15.31

14.81

16.61

18.77

17.49

20.63

23.80

27.28

23.55

22.52

- -

-0.46

-0.21

-0.42

0.14

1.77

0.89

0.88

0.64

0.95

1.47

3.48

2.84

-1.41

-7.15

- -

0.11

-0.14

0.13

0.48

0.26

0.13

1.28

1.51

0.21

-0.17

-1.51

-1.26

-1.78

-1.45

- -

0.24

0.13

0.02

- -

-11.77

-11.89

-11.75

-9.38

-8.30

-7.63

-6.53

-4.95

-3.27

0.16

2.91

1.46

-3.88

- -

-15.33

-15.39

-15.57

-6.40

-5.25

-4.75

-6.41

-10.09

-2.83

3.40

3.96

3.28

2.35

- -

117

120

125

131

144

150

168

176

181

182

- -

1,532

1,695

1,800

1,828

1,831

1,848

2,075

2,463

2,518

3,094

3,998

4,802

4,263

4,098

- -

13.20

12.94

12.66

14.43

15.18

12.42

12.14

11.68

10.88

12.77

16.16

15.18

1.10

-7.37

- -

116

130

152

143

141

147

190

229

254

289

378

422

453

- -

-54

-24

-50

212

112

110

137

221

585

499

-256

-1,302

- -

2.69

- -

73.44

- -

23.26

19.03

45.00

14.38

15.00

18.18

13.82

- -

-3.53

-1.44

-2.76

0.89

11.59

6.03

5.29

3.39

5.44

7.14

14.63

10.39

-6.01

-31.77

- -

265

269

235

339

399

591

663

725

1,400

1,722

1,819

1,162

1,534

- -

2,640

2,657

2,685

1,857

1,833

2,055

2,649

2,883

2,945

3,166

4,171

4,313

4,959

- -

-351

-410

-372

634

636

724

1,087

2,288

3,506

4,274

4,775

4,611

3,687

- -

18.04

- -

2.97

- -

6.90

7.61

4.76

5.17

5.69

7.50

7.59

- -

23.45

- -

4.60

- -

23.33

18.74

9.74

9.66

11.03

20.00

14.44

- -

182.45

-65.31

- -